drug

ambrisentan

1 story · latest Oct 29, 2026

Follow ambrisentan. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Jun 2007 · NDA022081
Brand: Letairis

Relationships

Developed by Gilead Sciences

Timeline

Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filing

Oct 29Quarterly updateGilead Sciences Merck & Co., Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.